Evidence mapPaperPMID 41735665Full record

ArticleAdvances in therapy2026

System Preparedness for Rising Kidney Replacement Therapy Demand: Late-Stage CKD Drives Costs, Healthcare Resource Utilisation and Environmental Impact in Switzerland.

Thomas Campbell-James, Stefan Buff, Giliane Nanchen, Andrew Hall, Thomas Rosemann, Lindsay Nicholson, Stacey Priest, Anthony Zara, Luke Hubbert, Caterina Vecchio Rodriguez and 2 more

Abstract read
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Thomas Campbell-JamesMedical Affairs, AstraZeneca AG, Baar, Switzerland.ORCID http://orcid.org/0000-0003-1648-0515
Stefan BuffMedical Affairs, AstraZeneca AG, Baar, Switzerland.
Giliane NanchenService of Nephrology, University Hospital of Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-8522-7524
Andrew HallZurich Kidney Center, University of Zurich (UZH), Zurich, Switzerland.
Thomas RosemannDepartment of Primary Care, University of Zurich (UZH), Zurich, Switzerland.ORCID http://orcid.org/0000-0002-6436-6306
Lindsay NicholsonMaverex Limited, Newcastle upon Tyne, UK.ORCID http://orcid.org/0009-0001-3088-7197
Stacey PriestEVERSANA, Burlington, ON, Canada.
Anthony ZaraEVERSANA, Burlington, ON, Canada.ORCID http://orcid.org/0000-0002-2723-3563
Luke HubbertMaverex Limited, Newcastle upon Tyne, UK.
Caterina Vecchio RodriguezSwiss Association of Kidney Patients, Zurich, Switzerland.
George WhartonDepartment of Health Policy, London School of Economics and Political Science (LSE), London, UK.
Menno PruijmService of Nephrology, University Hospital of Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland. menno.pruijm@chuv.ch.ORCID http://orcid.org/0000-0003-1027-1851

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic kidney disease (CKD) is a leading cause of global morbidity and mortality, affecting one in ten Swiss adults. Patient numbers are expected to increase due to demographic shift and increasing comorbidity rates, necessitating strategic healthcare planning. Holistic burden remains unknown and detailed projections-including expectations of prospective economic and environmental impact-are lacking. To inform Switzerland's public health strategies and support its 2050 net-zero healthcare goal, this study aims to forecast the multidimensional burdens of CKD.

methodsThe IMPACT-CKD microsimulation model was utilised to project CKD-progression and clinical, healthcare resource utilisation, economic, societal, and environmental outcomes in Switzerland over 10 years (2023-2032). Modelled individuals were assigned CKD-relevant characteristics-including kidney function, comorbidities and clinical events-based on real-world data. Individuals were categorised into non-CKD or one of six CKD stages and progressed through the disease, diagnosed or undiagnosed. Model inputs and outcomes were validated and calibrated against literature, real-world evidence, and expert consultation.

resultsBy 2032, IMPACT-CKD projects Switzerland's cases of CKD to rise by 6.7% (0.96m to 1.03m) with late-stage CKD and kidney replacement therapy (KRT) surging by 18.1% (437k to 516k) and 57.2% (8.4k to 13.2k). CKD-related healthcare costs are projected to increase by 27.6% (Swiss francs [CHF] 3.3b to CHF 4.2b), driven by a 77.3% rise KRT-related costs. CKD would account for 4.6% of the Swiss healthcare budget, incur CHF 12.9b in lost productivity, 43.2m missed workdays and CHF 606m in lost tax revenue. Greenhouse gas emissions are projected to increase by 12.9%, driven by rising dialysis demand.

conclusionIMPACT-CKD projects substantial increases in the multidimensional burdens of CKD in Switzerland. Impact could be mitigated via earlier detection and broader uptake of guideline-directed medical therapy. Comprehensive health policies and strategic public health planning are necessary to reduce burden and sustain Switzerland's 2050 net-zero healthcare ambition.

Indexed as

Health Care CostsRenal Insufficiency, ChronicRenal Replacement TherapyAdultAgedDisease ProgressionFemaleHealth ResourcesHumansMaleMiddle AgedSwitzerlandBurden of diseaseChronic kidney diseaseCostsDialysisEnvironmental impactEpidemiologyHealthcare expenditureHealthcare resource utilisationIMPACT-CKDKidney replacement therapyMicrosimulation model

Identifiers

PMID41735665
PMCPMC13065528

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.